Evicenter
P&T meetings

Dersimelagon (MT-7117)

Erythropoietic protoporphyria or X-linked protoporphyria

Manufacturer
LEO Pharma
Regulatory submission
NDA submitted June 2026
Last updated
100 sources

Product information and disease descriptionPlace of product in therapyApproaches to treatmentCurrent treatment options and standard of care

Management of acute phototoxic reactions

1 evidence topic · 1 source

Absence of an effective treatment for an established reaction

“No studies evaluating treatments for acute phototoxicity could be found” (opens the source at this quote in a new tab)

“Anecdotally, many patients choose to self-treat with ice, cold water, or cold compresses, resulting in minor relief, although others report that both cold and heat worsen symptoms” (opens the source at this quote in a new tab)

“Cold compresses or cooling devices may be considered for the treatment of phototoxic symptoms ( Table 2” (opens the source at this quote in a new tab)

“There is no evidence of benefit with narcotic analgesics, oral or topical corticosteroids, antihistamines, acetaminophen and non-steroidal anti-inflammatory drugs” (opens the source at this quote in a new tab)

“There are insufficient data to recommend these therapies” (opens the source at this quote in a new tab)

“The development of novel therapies to treat pain in protoporphyria patients is a large unmet need” (opens the source at this quote in a new tab)